Skip to content
FIND A HEALTH VALLEY ACTOR

What is Series: Swiss Biotech Center

Swiss Biotech Center what is series

Discover the Swiss Biotech Center, a leading research and development center in the field of biotechnology, in GGBa’s “What is Series”.       With its modern facilities and state-of-the-art technologies, Swiss Biotech Center (SBC) is a major player in the promotion of innovation and development of new products and technologies in the field of…

Read More

Swiss Venture Capital Report: CHF 1.1 Billion for Swiss startups

Swiss venture capital financing remained at the low level of the previous year in the first half of 2024, with CHF 1’082.4 Million going to 138 financing rounds. Nevertheless, there were also positive signs, such as an increase in investment in the biotech sector.     This half-year update to Swiss Venture Capital Report, published…

Read More

Four Swiss Health Valley biotech companies worth keeping an eye out for in 2024

Biotech

Labiotech.eu, a leading digital media covering the European Biotech industry, published a list of Swiss biotech companies to put on your radar.   Switzerland is home to a thriving biotech industry, with strong research institutions many companies leading the way in cutting-edge research  for new cancer treatments and immunotherapies, from startups to multinationals. Labiotech highlighted…

Read More

Lonza acquires a new manufacturing site in the US

Lonza expansion US

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced the signing of an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 Billion.     The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet demand for commercial mammalian contract…

Read More

Alithea Genomics closes CHF 2.8 Million in seed financing extension

Alithea-seed-extension

This milestone marks a significant step forward in the company’s journey to revolutionise large-scale RNA sequencing and transcriptomics.     Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by…

Read More

Two life sciences startups shortlisted for the 31st Prix Strategis

Prix strategis

Testmate Health and Seprify are among the eight semi-finalists of this year’s Prix Strategis.     Every year for almost 30 years, HEC Espace Entreprise has awarded the Prix Strategis to some of the most promising Swiss start-up with a prize of CHF 50’000. The Strategis Prize is a springboard for young companies with high…

Read More

BioLizard chooses Biopôle for its Swiss subsidiary

BioLizard

BioLizard is a Belgian bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry.     Liesbeth Ceelen, PhD, CEO of BioLizard, said: “We aim to meet the need for expertise and tools for digital transformation of biotech companies, including for AI-enabled, user-friendly software and data infrastructure.…

Read More

Oryl Photonics raises CHF 830,000 in seed funding

Oryl Photonics

The Vaud-based startup announces the successful conclusion of a CHF 830,000 seed fundraising. The round is backed by Swiss investors, including CADFEM International AG, S2S Ventures and several business angels.     This is a significant achievement for Oryl Photonics, a company pioneering the development of highly efficient solubility measurement for pharmaceutical and life science…

Read More

Successful € 5 Million Capital Increase for GeNeuro

GeNeuro

GeNeuro, a Geneva-based biopharmaceutical company focusing on treatments for neurodegenerative and autoimmune diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and severe neuropsychiatric consequences of COVID-19 (post-COVID), has successfully completed a €5 million capital increase.     The increase involved a private placement of 4,666,901 new GeNeuro ordinary bearer shares for specialized and strategic…

Read More

Nicolas Durand appointed Director of the Campus Biotech Foundation in Geneva

Nicolas Durand 2

Dr Nicolas Durand will step down from his CEO role at Abionic on 29 February to be at the steering wheel of the innovation centre from 1 March 2024     The Foundation Campus Biotech announced the appointment of its new Director, Dr Nicolas Durand. “With an extensive background in nanotechnologies applied to life sciences,…

Read More